Shinpoong Pharmaceutical Co Ltd (019175) - Total Liabilities

Latest as of March 2026: ₩79.62 Billion KRW ≈ $53.96 Million USD

Based on the latest financial reports, Shinpoong Pharmaceutical Co Ltd (019175) has total liabilities worth ₩79.62 Billion KRW (≈ $53.96 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Shinpoong Pharmaceutical Co Ltd to track the company's year-over-year net asset growth rate.

Shinpoong Pharmaceutical Co Ltd - Total Liabilities Trend (2014–2025)

This chart illustrates how Shinpoong Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See how much free cash does Shinpoong Pharmaceutical Co Ltd generate to measure how efficiently the company converts operating cash flow to free cash.

Shinpoong Pharmaceutical Co Ltd Competitors by Total Liabilities

The table below lists competitors of Shinpoong Pharmaceutical Co Ltd ranked by their total liabilities.

Company Country Total Liabilities
All In! Games S.A.
WAR:ALG
Poland zł26.57 Million
Betonjaya Manunggal Tbk
JK:BTON
Indonesia Rp148.36 Billion
Brite Tech Bhd
KLSE:0011
Malaysia RM70.81 Million
BTC Health Ltd
AU:BTC
Australia AU$248.95K
Frtek Co.Ltd
KQ:073540
Korea ₩10.01 Billion
Envoy Medical Inc.
NASDAQ:COCH
USA $15.71 Million
Bal Pharma Limited
NSE:BALPHARMA
India Rs2.93 Billion

Liability Composition Analysis (2014–2025)

This chart breaks down Shinpoong Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Shinpoong Pharmaceutical Co Ltd market cap and net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 3.20 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.27 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.21 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Shinpoong Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Shinpoong Pharmaceutical Co Ltd (2014–2025)

The table below shows the annual total liabilities of Shinpoong Pharmaceutical Co Ltd from 2014 to 2025.

Year Total Liabilities Change
2025-12-31 ₩81.74 Billion
≈ $55.39 Million
-2.70%
2024-12-31 ₩84.00 Billion
≈ $56.93 Million
+5.93%
2023-12-31 ₩79.30 Billion
≈ $53.74 Million
+157.66%
2022-12-31 ₩30.78 Billion
≈ $20.86 Million
-19.06%
2021-12-31 ₩38.03 Billion
≈ $25.77 Million
-66.30%
2020-12-31 ₩112.82 Billion
≈ $76.46 Million
-34.02%
2019-12-31 ₩170.99 Billion
≈ $115.87 Million
-1.43%
2018-12-31 ₩173.47 Billion
≈ $117.56 Million
-1.16%
2017-12-31 ₩175.50 Billion
≈ $118.93 Million
-12.09%
2016-12-31 ₩199.64 Billion
≈ $135.29 Million
-7.52%
2015-12-31 ₩215.87 Billion
≈ $146.29 Million
-0.88%
2014-12-31 ₩217.78 Billion
≈ $147.59 Million
--

About Shinpoong Pharmaceutical Co Ltd

KO:019175 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$15.18 Million
₩22.40 Billion KRW
Market Cap Rank
#25911 Global
#1933 in Korea
Share Price
₩11250.00
Change (1 day)
+5.24%
52-Week Range
₩10690.00 - ₩28450.00
All Time High
₩242550.07
About

Shinpoong Pharmaceutical Co.,Ltd, together with its subsidiaries, manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products, as well as antivirals, anticancer drugs, painkillers, anti-inflammatory products, and anthelmintics. It provides active pharmaceutical ingredients; Pyramax, an anti-malarial dru… Read more